Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA) from its SEC filings: 2025 revenue $1.9 billion (-40% vs the year before), net margin -145%, free cash flow -$2.1 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $1.9 billion |
| Revenue growth | -40% |
| Net income | -$2.8 billion |
| Net margin | -145.2% |
| Free cash flow | -$2.1 billion |
| Diluted EPS | $-7.26 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +2% |
| Cash | $1.7 billion |
| Long-term debt | $591.0 million |
| Share count, 1 year | +3% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.